Scpharmaceuticals Net Tangible Assets from 2010 to 2024

SCPH Stock  USD 3.74  0.14  3.89%   
Scpharmaceuticals' Net Tangible Assets are increasing with slightly volatile movements from year to year. Net Tangible Assets are predicted to flatten to about 54.8 M. Net Tangible Assets is the total assets of Scpharmaceuticals minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. View All Fundamentals
 
Net Tangible Assets  
First Reported
2015-12-31
Previous Quarter
75.8 M
Current Value
63.4 M
Quarterly Volatility
46.3 M
 
Yuan Drop
 
Covid
Check Scpharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Scpharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 502.9 K, Interest Expense of 8.5 M or Selling General Administrative of 56 M, as well as many indicators such as Price To Sales Ratio of 14.22, Dividend Yield of 0.0 or PTB Ratio of 6.81. Scpharmaceuticals financial statements analysis is a perfect complement when working with Scpharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Scpharmaceuticals Correlation against competitors.
For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.

Latest Scpharmaceuticals' Net Tangible Assets Growth Pattern

Below is the plot of the Net Tangible Assets of Scpharmaceuticals over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Scpharmaceuticals' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Scpharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Tangible Assets10 Years Trend
Slightly volatile
   Net Tangible Assets   
       Timeline  

Scpharmaceuticals Net Tangible Assets Regression Statistics

Arithmetic Mean29,693,159
Coefficient Of Variation171.11
Mean Deviation47,248,815
Median51,365,000
Standard Deviation50,809,206
Sample Variance2581.6T
Range143.1M
R-Value0.77
Mean Square Error1123.7T
R-Squared0.60
Significance0.0007
Slope8,769,613
Total Sum of Squares36142.1T

Scpharmaceuticals Net Tangible Assets History

202454.8 M
202383.3 M
202272.4 M
202163.1 M
202082.2 M
201951.4 M
201878.7 M

About Scpharmaceuticals Financial Statements

Investors use fundamental indicators, such as Scpharmaceuticals' Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Scpharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Net Tangible Assets83.3 M54.8 M

Currently Active Assets on Macroaxis

When determining whether Scpharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scpharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scpharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scpharmaceuticals Stock:
Check out the analysis of Scpharmaceuticals Correlation against competitors.
For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.95)
Revenue Per Share
0.741
Quarterly Revenue Growth
1.641
Return On Assets
(0.42)
Return On Equity
(1.67)
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.